Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

December 30, 2025 Lung Cancer Considered -- Immunotherapy Toxicity: Myths & Pearls
Since the first immunotherapy agent for lung cancer was approved in 2015, this class of drugs has captured the imagination and the narrative for the treatment of driver negative lung cancer. Immunotherapy is now the standard of care for most patients with lung cancer in some form. And while not all patients benefit, those that do, have the chance for transformative benefit. In today’s episode, we focus not on the benefit of immunotherapy, which can be massive, but on the toxicity of immunotherapy.
Guest: Dr. Jarushka Naidoo, a consultant medical oncologist at Beaumont Hospital Dublin and a Professor in the Royal College of Surgeons in Ireland. She currently serves as national lung cancer lead for Cancer Trials Ireland and serves on several international guideline panels including ASCO and SITC
19 min
December 23, 2025 Lung Cancer Considered: A New Shot at Progress: Amivantamab Goes SubQ
The FDA has approved subcutaneous amivantamab. Join host Dr. Narjust Florez and guests, Dr. Natasha Leighl and Dr. Federico Cappuzzo, as they explore the science and convenience factor, as well as what this shift means for patients, clinicians, and oncology practice.
36 min
December 16, 2025 Lung Cancer Considered at the ASCO IASLC 2025 North American Conference on Lung Cancer
In this special episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the IASLC | ASCO 2025 North America Conference on Lung Cancer.
Dr. Igor Odintsov discusses updates in diagnostic pathology, including the integration of next-gen sequencing into the patient's journey. Dr. Byoung Chul Cho shares data from the phase 3 trial of gotistobart vs. docetaxel in patients with metastatic squamous cell lung cancer. Dr. Sulin Wu shares insights on the role of family history in lung cancer among women and low-exposure smokers.
38 min
December 09, 2025 Lung Cancer Care in New Zealand
In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with two thoracic oncologists practicing in New Zealand—Dr. Laird Cameron from Auckland Hospital and Dr. Annie Wong from the University of Otago—about the unique challenges and approaches to lung cancer care in their island nation of 5.4 million people.
The conversation explores New Zealand's healthcare coverage system, patient population characteristics including smoking rates, the current state of lung cancer screening programs, and how molecular testing is conducted for non-small cell lung cancer patients.
Drs. Cameron and Wong discuss access to targeted therapies and immunotherapy, the drug approval process in New Zealand, cultural considerations and health disparities affecting lung cancer treatment, and the clinical research infrastructure available in the country. This global perspective highlights how IASLC members face different regional challenges while working toward common goals in advancing lung cancer care.
25 min
December 05, 2025 LCC in Spanish: Mujeres and oncologia toracica – Latinoamerica
As part of IASLC’s Lung Cancer Considered World Language Series, host Dr. Narjust Florez leads a Spanish-language discussion with three leaders in thoracic oncology across Latin America: Dr. Mónica Castro, Dr. Dolores de la Mata, and Dr. Maritza Ramos Ramírez.
They discuss the current landscape of lung cancer in women across the region including unique risk factors and social challenges. The guests share their career paths, the barriers women face in thoracic oncology in Latin America, and their advice for the next generation entering the field.
48 min
December 02, 2025 IASLC Lung Cancer Considered: ADCs in EGFR Mutant NSCLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugates (ADCs) for EGFR-mutant non-small cell lung cancer (NSCLC). They discuss new approvals of datopotamab deruxtecan (in the United States) and sacituzumab tirumotecan (in China), key findings from the TROPION and OptiTROP trials, and emerging agents. The conversation highlights the advances in efficacy, safety, and combination strategies that are shaping the evolving treatment landscape for patients with EGFR-mutant NSCLC.
Guest: Li Zhang, MD
Professor, Medical Oncology Department
Sun Yat-Sen University Cancer Center
No Social
Guest: Elaine Shum, MD
Assistant Professor
Director of Cancer Screening Programs
New York University Perlmutter Cancer Center
37 min
November 18, 2025 Can I Take That? Integrative Medicine and Lung Cancer
Join Dr. Narjust Florez as she explores complementary and integrative medicine in lung cancer care with leading experts Dr. Ting Bao, Dr. Jun J. Mao, and Dr. Lisa Davis. This episode clarifies the differences between alternative, complementary, and integrative approaches while addressing oncologists' concerns about safety and drug interactions. Learn where to find reliable information, what the research shows about treatments like acupuncture and supplements, and how patients can safely incorporate these therapies into their cancer journey.
Guests:
Ting Bao, MD, MS, FSIO
Co-Director, Leonard P. Zakim Center for Integrative Therapies and Healthy Living
Member of the Faculty, Harvard Medical School
Dana-Farber Cancer Institute
Jun J. Mao, MD, MSCE
Chief, Integrative Medicine Service
Laurance S. Rockefeller Chair in Integrative Medicine
Professor of Medicine, Weill Cornell Medicine
Memorial Sloan Kettering Cancer Center
Lisa Davis, PharmD, FCCP, BCPS, BCOP,
Clinical Professor, Pharmacy Practice & Science
The University of Arizona, R. Ken Coit College of Pharmacy
46 min
November 14, 2025 LCC in Spanish: ¿Pulmón Vital: donde la ciencia se encuentra con la medicina tradicional
As part of IASLC’s Lung Cancer Considered world language series, host Dr. Narjust Florez discusses the role of complementary medicine in cancer care in Spanish with Dr. Cittim Bernardo Palomares and Dr. Eduardo Rios-Garcia.
They discuss the role of integrative medicine in lung cancer, how to access accurate information, and the benefits of certain forms of complementary and integrative medicine for patients and their caregivers.
51 min
November 07, 2025 LCC in Georgian: WCLC 2025 Highlights
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages.
In this episode, host Dr. Elene Mariamidze moderates a discussion in Georgian about highlights from the conference with Dr. Salome Begijanashvili, Dr. Beka Shubitidze, and Dr. Mariam Tchiabrishvili.
32 min
November 04, 2025 The New Face of Lung Cancer: A Conversation with Two Young Lung Cancer Warriors
In this episode of Lung Cancer Considered, host Dr. Narjust Florez speaks with two remarkable young lung cancer advocates Samantha Murell and Megan Flanagan, who are redefining what it means to live with the disease. They share their journeys from diagnosis to advocacy, shedding light on the challenges young patients face, breaking misconceptions, and offering hope to others along the way.
45 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.